Kukolja S, Wright W E, Quay J F, Pfeil-Doyle J, Draheim S E, Eudaly J A, Johnson R J, Ott J L, Counter F T, Cooper R D
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.
J Med Chem. 1988 Oct;31(10):1987-93. doi: 10.1021/jm00118a022.
A number of 7-(arylacetamido)-3-substituted cephalosporins were prepared and tested in animals for oral absorbability. Bioavailability in mice, rats, dogs, and monkeys was determined after oral or parenteral administration. Oral bioavailability of five compounds selected for more intensive study was generally higher than that of penicillin V in all species tested. The results of ED50 testing against experimental infections in mice generally supported the bioavailability studies. Antibiotic activities were evaluated against Gram-positive and Gram-negative organisms with some derivatives expressing in vitro activity similar to cefaclor. The plasma half-life in rats was relatively short and the plasma curves were strongly influenced by probenecid, indicating rapid renal secretion. Some 7-(arylacetamido)-3-chloro cephalosporins are orally absorbed in animals to a greater extent than penicillin V, and antibacterial agent of proven clinical utility.
制备了多种7-(芳基乙酰胺基)-3-取代头孢菌素,并在动物身上测试其口服吸收性。经口服或肠胃外给药后,测定了小鼠、大鼠、狗和猴子的生物利用度。在所有受试物种中,挑选出的五种用于更深入研究的化合物的口服生物利用度通常高于青霉素V。针对小鼠实验性感染的半数有效剂量(ED50)测试结果总体上支持了生物利用度研究。评估了这些化合物对革兰氏阳性菌和革兰氏阴性菌的抗菌活性,一些衍生物表现出与头孢克洛相似的体外活性。这些化合物在大鼠体内的血浆半衰期相对较短,血浆曲线受丙磺舒的影响很大,表明其经肾脏快速分泌。一些7-(芳基乙酰胺基)-3-氯头孢菌素在动物体内的口服吸收程度比青霉素V更高,是已证实具有临床效用的抗菌剂。